TY - T1的艾滋病结核病的影响,tuberculosis-IRIS,强的松在肺功能JF -欧洲呼吸杂志》乔和J - 10.1183/13993003.01692 -2019欧元SP - 1901692 AU -卡里Stek AU -布莱恩Allwood AU -杜埃尔莎Bruyn盟Jozefien Buyze AU -夏洛特Schutz盟弗里德里希·Thienemann盟阿黛尔朗伯德盟-罗伯特·J·威尔金森盟格雷姆Meintjes盟Lutgarde Lynen Y1 - 2019/01/01 UR - //www.qdcxjkg.com/content/early/2019/12/04/13993003.01692 - 2019. -抽象N2 -后残余肺损伤是常见的治疗肺结核。艾滋病结核病患者的肺功能数据稀缺,特别是在矛盾的背景下tuberculosis-associated免疫重建炎性综合症(TB-IRIS)和预防强的松。我们旨在确定的流行艾滋病结核病患者的肺功能异常和CD4数量≤100个细胞·μL−1和评估预防性强的松的影响和发展的矛盾TB-IRIS肺损伤。我们进行肺量测定法、6分钟步行试验和胸部x线摄影在基线(周0),星期4,12日和28日在参与者的PredART试验,评估一个28天的强的松防止TB-IRIS艾滋病结核病患者开始抗逆转录病毒治疗。153名参与者接受肺量测定法和/或在一个或多个时间点6分钟步行试验。异常的肺量测定法测量中66%的参与者在0和50%每周28;用力肺活量低是最常见的异常。胸片显示,大多数参与者很少或没有异常。强的松使用导致42米大6分钟步行距离和更高比例的4.9%预测用力呼气量在1 s 4周;这些差异从第12周开始不再明显不同。TB-IRIS没有显著影响肺功能结果。Residual pulmonary impairment is common in HIV-associated tuberculosis. In patients with low CD4 counts, neither prophylactic prednisone as used in our study nor the development of TB-IRIS significantly affected week 28 pulmonary outcome.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Stek has nothing to disclose.Conflict of interest: Dr. Allwood has nothing to disclose.Conflict of interest: Dr. Du Bruyn has nothing to disclose.Conflict of interest: Dr. Buyze has nothing to disclose.Conflict of interest: Dr. Schutz has nothing to disclose.Conflict of interest: Dr. Thienemann has nothing to disclose.Conflict of interest: Dr. Lombard has nothing to disclose.Conflict of interest: Dr. Wilkinson reports grants from Wellcome, grants from UK research and Innovation, grants from National Institutes of Health, grants from Foundation for the National Institues of Health, grants from European and Developing Countries Clinical Trials Partnership, during the conduct of the study.Conflict of interest: Dr. Meintjes has nothing to disclose.Conflict of interest: Dr. Lynen has nothing to disclose. ER -